Page last updated: 2024-09-05

sb 203580 and arenobufagin

sb 203580 has been researched along with arenobufagin in 1 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (arenobufagin)	Trials (arenobufagin)	Recent Studies (post-2010) (arenobufagin)
3,489	4	1,137	32	0	29

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bian, B; Han, L; Hayashi, H; Shimada, R; Si, N; Takagi, N; Yuan, B; Zhao, HY	1

Other Studies

1 other study(ies) available for sb 203580 and arenobufagin

Article	Year
Cytocidal effects of arenobufagin and hellebrigenin, two active bufadienolide compounds, against human glioblastoma cell line U-87. International journal of oncology, 2018, Volume: 53, Issue:6 Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Bufanolides; cdc25 Phosphatases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imidazoles; MAP Kinase Signaling System; Pyridines; Rats; Survivin	2018

Article

Year

Cytocidal effects of arenobufagin and hellebrigenin, two active bufadienolide compounds, against human glioblastoma cell line U-87.

International journal of oncology, 2018, Volume: 53, Issue:6

Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Bufanolides; cdc25 Phosphatases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imidazoles; MAP Kinase Signaling System; Pyridines; Rats; Survivin

2018